![](https://news.europawire.eu/wp-content/uploads/2023/03/OncoC4-licenses-next-generation-anti-CTLA-4-monoclonal-antibody-candidate-to-BioNTech-144x144.jpg)
(IN BRIEF) Pfizer and BioNTech have announced positive topline results from a Phase 1/2 study of their mRNA-based combination vaccine program for influenza and COVID-19. The lead formulations showed robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains. … Read the full press release